Medical Testing · us
Distinguishing Infections Through the Immune Response: Access MeMed BV Receives FDA Clearance, Providing Clues in as Little as 15 Minutes
Bacterial and viral infections often have similar symptoms, but antibiotic decisions cannot always wait. This blood test brings host-response analysis to existing laboratory instruments and is intended for patients as young as 90 days old. Beyond speed, the key is how it is integrated with clinical judgment.
When patients present with fever and fatigue, physicians often must decide whether to use antibiotics before the cause of infection is clear. On November 3, Beckman Coulter announced that its Access MeMed BV blood test, which helps distinguish bacterial from viral infections, had received marketing clearance from the U.S. Food and Drug Administration (FDA), providing an additional basis for assessment during this waiting period.
According to FDA records, the clearance decision was dated October 19, 2026, before the company's announcement. Submission K261109 was reviewed through the traditional 510(k) pathway and determined to be substantially equivalent to an existing legally marketed device. The significance of this development is the extension of MeMed's host-response test to Beckman Coulter's laboratory analysis platforms, rather than the first U.S. clearance for this type of test.
Access MeMed BV reads the body's response to infection. It measures three immune-response proteins in serum or plasma—TRAIL, IP-10, and C-reactive protein (CRP)—and generates a score reflecting the likelihood of bacterial infection. This offers another perspective on infection, but the score itself does not identify the bacterial species responsible and must be interpreted alongside clinical assessment and other test results.
According to the intended use published by the company, the test is intended for adults and children as young as 90 days old with suspected acute infection and symptoms lasting fewer than seven days. Use settings include samples collected in emergency departments, urgent care, and at hospital admission. The product can run on the DxI 9000 and Access 2 immunoassay analyzers. The claim of “as little as 15 minutes” specifically refers to testing performance on the DxI 9000 and cannot be taken as applying to every platform or as the total time from blood collection to the physician receiving the result.
Whether existing instruments can accommodate a new test affects the barriers to hospital adoption. For laboratories already equipped with compatible platforms, this clearance offers a way to expand their test menus. However, whether the test can support prescribing decisions in time also depends on how sample submission, scheduling, and result reporting connect with clinical workflows.
The research evidence also requires distinctions between platforms and uses. Patient Care Online noted that the Apollo diagnostic accuracy study cited in the company's announcement used the MeMed Key platform, so its performance figures cannot be treated directly as validation results for this Access version. The Tampa General Hospital healthcare resource analysis cited in the announcement received support from MeMed in the form of reagents and funding for a research assistant. These data can inform evaluation, but their interpretation must still account for study design and conflicts of interest.
The opportunity this test offers is to give physicians an additional layer of host-response evidence while pathogen information remains incomplete. How much it can reduce unnecessary antibiotic use across different hospitals, and whether it improves patient care, still require ongoing assessment in clinical settings actually using the Access platform.